Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis.

Trial Profile

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPID-axSpA
  • Sponsors UCB
  • Most Recent Events

    • 08 Nov 2017 Results assessing improvements in tenderness at entheseal sites in males and females with axSpA treated with Certolizumab Pegol for <4 years presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results of four year imaging outcomes presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 14 Jun 2017 According to a UCB media release, four-year imaging results from this study were reported at the Annual European Congress of Rheumatology (EULAR) 2017 and the result were also published in the journal Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top